Health Care • Medicinal Chemicals and Botanical Products
$76.75 ▲ +3.76
(+5.15%)
MKT CAP: $128.15B • VOL: 12.53M
52W L $55 52W H $80
MO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $23.28B | $24.02B | $24.48B |
| YoY Revenue Growth % | -3.1% | -1.9% | — |
| Gross Profit | $14.54B | $14.37B | $10.77B |
| Gross Margin % | 62.5% | 59.8% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $9.90B | $11.24B | $11.55B |
| Operating Margin % | 42.5% | 46.8% | 47.2% |
| Net Income (GAAP) | $6.95B | $11.26B | $8.13B |
| EBITDA (Normalized) | $10.07B | $11.35B | $12.43B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $9.29B | $8.75B | $9.29B |
| Capital Expenditures (CapEx) | $216.0M | $142.0M | $1.10B |
| Free Cash Flow (FCF) | $9.07B | $8.61B | $8.19B |
| FCF Margin % | 39.0% | 35.9% | 33.4% |
| Return on Invested Capital (ROIC %) | 48.4% | 49.2% | 21.4% |
| Cash & Short-Term Equivalents | $4.47B | $3.13B | $7.75B |
| Total Debt (Short + Long Term) | $24.14B | $23.40B | $16.49B |
| Total Stockholders' Equity | -$3.50B | -$2.24B | $33.83B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MO.